SPRINGFIELD, Mass. Four local students have been named to the 2023 spring dean’s list at Springfield College. William Banks from Jefferson has a primary major of physical education. Christa Carr from Pittsfield has a primary major of athletic training. Emma Hanna from Bowdoin has a primary major of health science/pre-occupational therapy. Kaitlin Morrison from […]
E-Mail
IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, North Carolina UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.